These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8725734)

  • 41. [Effects of aprotinin on blood loss reduction in children undergoing repair of tetralogy of Fallot].
    Imai M; Yamaguchi M; Ohashi H; Oshima Y; Aoyama M; Tanaka T; Ogawa K
    Nihon Kyobu Geka Gakkai Zasshi; 1997 Oct; 45(10):1706-9. PubMed ID: 9394581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Platelet dysfunction during cardiopulmonary bypass surgery. With special reference to platelet membrane glycoproteins.
    Kondo C; Tanaka K; Takagi K; Shimono T; Shinpo H; Yada I; Yuasa H; Kusagawa M; Akamatsu N; Tanoue K
    ASAIO J; 1993; 39(3):M550-3. PubMed ID: 8268596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Arachidonic acid metabolism and effectiveness of aprotinin treatment during cardiopulmonary bypass].
    Nagaoka H; Innami R; Funakoshi N; Fujiwara A; Itoh J
    Nihon Kyobu Geka Gakkai Zasshi; 1991 Sep; 39(9):1723-30. PubMed ID: 1720445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass.
    Shigeta O; Kojima H; Jikuya T; Terada Y; Atsumi N; Sakakibara Y; Nagasawa T; Mitsui T
    Circulation; 1997 Jul; 96(2):569-74. PubMed ID: 9244227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study.
    Casas JI; Zuazu-Jausoro I; Mateo J; Oliver A; Litvan H; Muñiz-Díaz E; Arís A; Caralps JM; Fontcuberta J
    J Thorac Cardiovasc Surg; 1995 Oct; 110(4 Pt 1):1107-17. PubMed ID: 7475139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aprotinin administration in the pericardial cavity does not prevent platelet activation.
    Maquelin KN; Nieuwland R; Lentjes EG; Böing AN; Mochtar B; Eijsman L; Sturk A
    J Thorac Cardiovasc Surg; 2000 Sep; 120(3):552-7. PubMed ID: 10962418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release.
    Ashraf S; Tian Y; Cowan D; Nair U; Chatrath R; Saunders NR; Watterson KG; Martin PG
    Ann Thorac Surg; 1997 Jan; 63(1):68-73. PubMed ID: 8993243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of aprotinin during cardiopulmonary bypass in patients treated with acetylsalicylic acid.
    Ivert T; Intonti M; Stain-Malmgren R; Dumitrescu A; Blombäck M
    Scand Cardiovasc J; 1998; 32(5):289-95. PubMed ID: 9835004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The blood saving potential of vortex versus roller pump with and without aprotinin.
    Wahba A; Philip A; Bauer MF; Kaiser M; Aebert H; Birnbaum DE
    Perfusion; 1995 Sep; 10(5):333-41. PubMed ID: 8601046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass.
    Ray MJ; Marsh NA; Just SJ; Perrin EJ; O'Brien MF; Hawson GA
    Ann Thorac Surg; 1997 Jan; 63(1):57-63. PubMed ID: 8993241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage.
    Mössinger H; Dietrich W
    Ann Thorac Surg; 1998 Jun; 65(6 Suppl):S45-50; discussion S50-1, S74-6. PubMed ID: 9647138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet preservation during cardiopulmonary bypass with aprotinin.
    Wildevuur CR; Eijsman L; Roozendaal KJ; Harder MP; Chang M; van Oeveren W
    Eur J Cardiothorac Surg; 1989; 3(6):533-7; discussion 537-8. PubMed ID: 2483979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study.
    Lavee J; Raviv Z; Smolinsky A; Savion N; Varon D; Goor DA; Mohr R
    Ann Thorac Surg; 1993 Jan; 55(1):114-9. PubMed ID: 7678061
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of recombinant aprotinin on platelet activation in patients undergoing open heart surgery.
    Matzdorff AC; Green D; Cohen I; Bauer KD
    Haemostasis; 1993; 23(6):293-300. PubMed ID: 7518406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass.
    Rinder CS; Mathew JP; Rinder HM; Bonan J; Ault KA; Smith BR
    Anesthesiology; 1991 Oct; 75(4):563-70. PubMed ID: 1718190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aprotinin reduces the expression of p-selectin on the surface of platelet and leukocyte-platelet conjugates.
    Inui K; Shimazaki Y; Watanabe T; Kuraoka S; Uesho K; Uchida T; Shiono S
    Artif Organs; 1998 Dec; 22(12):1018-22. PubMed ID: 9876093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aprotinin in perspective.
    Westaby S
    Ann Thorac Surg; 1993 Apr; 55(4):1033-41. PubMed ID: 7682054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiopulmonary bypass leads to a preferential loss of activated platelets. A flow cytometric assay of platelet surface antigens.
    Wahba A; Black G; Koksch M; Rothe G; Preuner J; Schmitz G; Birnbaum DE
    Eur J Cardiothorac Surg; 1996; 10(9):768-73. PubMed ID: 8905280
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding.
    Uthoff K; Zehr KJ; Geerling R; Herskowitz A; Cameron DE; Reitz BA
    Circulation; 1994 Nov; 90(5 Pt 2):II269-74. PubMed ID: 7955264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aprotinin restores the adhesive capacity of dysfunctional platelets.
    Bradfield JF; Bode AP
    Thromb Res; 2003 Feb; 109(4):181-8. PubMed ID: 12757772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.